Author | Frank J. Brescia, MD

Articles

Irinotecan/Gemcitabine Combination Chemotherapy in Pancreatic Cancer

March 02, 2001

Gemcitabine (Gemzar) and irinotecan (CPT-11, Camptosar) are active cytotoxic drugs against pancreatic cancer. Preclinical data evaluating the combination of gemcitabine and irinotecan suggest dose-dependent synergistic

Docetaxel Followed by Gemcitabine and Irinotecan in Solid Tumors

January 01, 2001

ByCaio Max S. Rocha Lima, MD

Carol A. Sherman, MD

Frank J. Brescia, MD

Mark R. Green, MD

Docetaxel (Taxotere), gemcitabine (Gemzar), and irinotecan (Camptosar, CPT-11) are active single agents in a variety of solid tumors. In combination, synergism may be schedule dependent. Preclinical studies suggested

Irinotecan in the Management of Patients With Pancreatic Cancer

December 03, 2000

ByMark R. Green, MD

Melinda Harper, RN

Ahmad R. Safa, MD, PhD

Carol A. Sherman, MD

Chaudry M. Mushtaq, MD

Hamid Bahadori, MD

Frank J. Brescia, MD

Caio Max S. Rocha Lima, MD

Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan ( Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with